Article:The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus. (5964532)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q55114052. Its title is The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus. and the publication date was 2018-05-07. The initial author is You Lv.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: Journal of Diabetes Research

The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus

  • You Lv
  • Xue Zhao
  • Weiying Guo
  • Ying Gao
  • Shuo Yang
  • Zhuo Li
  • Guixia Wang

Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin, China

Publication date (collection): /2018

Publication date (epub): 5/2018

Abstract

Metabolic diseases, especially diabetes mellitus, have become global health issues. The etiology of diabetes mellitus can be attributed to genetic and/or environmental factors. Current evidence suggests the association of gut microbiota with metabolic diseases. However, the effects of glucose-lowering agents on gut microbiota are poorly understood. Several studies revealed that these agents affect the composition and diversity of gut microbiota and consequently improve glucose metabolism and energy balance. Possible underlying mechanisms include affecting gene expression, lowering levels of inflammatory cytokines, and regulating the production of short-chain fatty acids. In addition, gut microbiota may alleviate adverse effects caused by glucose-lowering agents, and this can be especially beneficial in diabetic patients who experience severe gastrointestinal side effects and have to discontinue these agents. In conclusion, gut microbiota may provide a novel viewpoint for the treatment of patients with diabetes mellitus.

Paper

1. Introduction

Over the past few decades, metabolic diseases such as type 2 diabetes mellitus (T2DM), obesity, dyslipidemia, and cardiovascular diseases have become major public health issues all over the world. Accordingly, an increasing amount of research has been conducted to further investigate the pathogenesis, phenotypes, and treatments of such diseases. One of the most common metabolic disorders is T2DM, which is characterized by chronic hyperglycemia that can be attributed to genetic and/or environmental factors. Recently, the role played by gut microbiota in T2DM has gained increasing attention, with several studies investigating the composition and function of gut microbiota in T2DM [[1]].

It was found that, for a standard-weight male, the ratio of bacterial cells to human cells is approximately 1 : 3, with an uncertainty of 25% and a variation of 53% [[2]]. Several studies reported an association between gut microbiota and metabolic diseases [[3][9]], with some studies presenting the differences between gut microbiota in T2DM patients and healthy individuals [[3], [10]]. For example, Qin et al. [[11]] reported that many opportunistic pathogens, such as Bacteroides caccae, Clostridium hathewayi, Clostridium ramosum, Clostridium symbiosum, Eggerthella lenta, and Escherichia coli, are enriched in T2DM patients. In addition, Karlsson et al. [[12]] reported an increase in Lactobacillus spp. (Lactobacillus gasseri JV-V03, Lactobacillus gasseri SJ-9E-US, Lactobacillus gasseri 202-4, and Lactobacillus salivarius ACS-116-V-Col5a) and a decrease in Clostridium spp. (Clostridium beijerinckii NCIMB 8052, Clostridium sp. 7_2_43FAA, Clostridium botulinum B str. Eklund 17B, Clostridium botulinum E3 str. Alaska E43, and Clostridium thermocellum DSM 1313) in T2DM patients. Treatment with metformin affects gut microbiota, and thus, it might be an important confounder in the above studies. Gut microbiota were found to control body weight after bariatric surgery, regulate plasma glucose and insulin levels, maintain the intestinal epithelial barrier integrity, and lower the levels of inflammatory cytokines [[13][16]]. Moreover, some probiotic supplements exhibit beneficial metabolic properties [[15][17]]. All this information suggests that gut microbiota may be involved in the etiology of diabetes mellitus.

Short-chain fatty acids (SCFAs) including acetate (C2), propionate (C3), butyrate (C4), and valerate (C5) are produced by anaerobic bacteria through the fermentation of nondigestible dietary polysaccharides in the colon [[18][20]]. Some researchers suggested that a common form of gut microbiota alteration in T2DM is the reduction in butyrate-producing bacteria [[11], [21]]. Sodium butyrate was found to lower plasma glucose and lipid levels, improve insulin resistance, and reduce gluconeogenesis in diabetic rats [[22]]. Thus, SCFAs might have a promising role in the prevention and treatment of diabetes mellitus.

Currently available therapeutic options for T2DM, especially glucose-lowering agents, target different pathophysiologic processes. A large body of evidence suggests that gut microbiota and SCFAs exhibit positive effects on glucose-lowering agents in T2DM. Glucose-lowering agents can influence the composition of gut microbiota [[23], [24]] and affect the production of SCFAs, thereby leading to significant beneficial effects [[1], [25], [26]]. Moreover, adverse effects of glucose-lowering agents may be improved by altered gut microbiota [[27], [28]]. This review summarizes current information on the relationship between frequently used glucose-lowering agents and gut microbiota (Table 1) to better understand the role of the intestinal microenvironment in the treatment of diabetes mellitus.

2. Metformin and Gut Microbiota

2.1. Metformin Mechanism of Action and Side Effects

Metformin is a biguanide that reduces hepatic glucose production, increases glucose uptake by peripheral tissues, and activates AMP-dependent protein kinase (AMPK). Metformin is actively transported into cells by organic cation transporters (OCT) [[29], [30]]. The mechanism of action of metformin is not yet fully understood. In an experimental study on mice with alanine knock-in mutations in both acetyl-CoA carboxylase (Acc) 1 (Ser79) and Acc2 (Ser212), treatment with metformin reduced hepatic lipogenesis and lipid accumulation via activating AMPK and inhibited both Acc1 and Acc2, thereby increasing insulin sensitivity [[31]]. Duca et al. [[32]] found that metformin could activate duodenal mucosal AMPK and attenuate hepatic glucose production in a rat model of high-fat diet (HFD). In addition, Miller et al. [[33]] found that metformin lowers the fasting glucose level by inhibiting glucagon-stimulated cyclic adenosine monophosphate production, which leads to reduced protein kinase A activity and glucagon-stimulated glucose output. Metformin was also found to alter intestinal microbiota [[34]].

Currently, metformin is the first-line treatment for T2DM and is recommended by the American Diabetes Association and the European Association for the Study of Diabetes with proven efficacy, safety, and low cost [[35]]. It can lower plasma glucose and insulin levels, improve lipid profiles, and promote modest weight loss. An extended-release formulation of metformin that has fewer gastrointestinal (GI) side effects, for example, diarrhea, anorexia, nausea, and metallic taste, is also available [[21], [29]]. About 30% of the patients treated with metformin report suffering from GI adverse effects [[1]]. In a previous clinical study in which 360 T2DM patients were administered a new prescription of metformin for 3 months, about 88% of the participants reported single or multiple GI symptoms, including diarrhea, heartburn, and nausea [[36]]. Possible underlying mechanisms for metformin adverse effects include stimulation of intestinal serotonin secretion, changes in incretin and glucose metabolism, bile salt malabsorption, and high intestinal metformin concentrations after oral administration [[37]]. Since OCT1 is involved in the absorption of metformin from the intestinal lumen, its inhibition results in increased metformin intolerance [[37]]. Recent data illustrated that delayed-release metformin performs its action predominantly in the intestine, so it is considered to be safe for T2DM patients with renal impairment [[38]].

2.2. The Effect of Metformin on Gut Microbiota in T2DM

Metformin has pleiotropic effects. It accumulates mainly in the intestine, where its concentration is nearly 300 times higher than its plasma concentration [[39]]. Thus, the intestine is the major site of metformin exposure and is responsible for its glucose-lowering effect [[38]]. In 1984, Bonora et al. [[40]] found that intravenous administration of metformin did not improve glucose metabolism compared to oral administration, which suggests the importance of the intestine in the regulation of glucose metabolism by metformin. Metformin was found to increase the life span of Caenorhabditis elegans cocultured with Escherichia coli by altering microbial folate and methionine metabolism [[41]], which suggests that the effects of metformin on aging in nematodes are microbiota dependent. Recently, the relationship between metformin and the gut has been comprehensively reviewed [[21]]; researchers indicated that metformin can affect the gut microenvironment by modulating glucose uptake and utilization, increasing glucagon-like peptide-1 (GLP-1) and bile acid levels and altering gut microbiota. In conclusion, the interaction between metformin and gut microbiota may contribute to the pleiotropic effects of metformin.

A large body of evidence confirms the effects of metformin on intestinal microbiota. The abundance of Akkermansia muciniphila was found to be decreased in obesity and diabetes [[9]], while higher baseline levels were associated with improvements in the cardiometabolic parameters of obesity [[11], [42]]. Experimental studies revealed that the abundances of Akkermansia muciniphila [[43], [44]] and Clostridium cocleatum [[43]] increased significantly in HFD-fed mice after metformin treatment. The higher abundance of Akkermansia muciniphila was involved in maintaining mucin layer integrity [[45], [46]], and the changes in gut microbiota were attributed to SCFA-producing bacteria in human and animal guts [[45], [46]]. It is suggested that the effects of metformin on the abundance of these species may indirectly contribute to its modulatory effects on glucose metabolism and other metabolic processes. These results suggest that the therapeutic effect of metformin might be partially mediated by the intestinal tract.

Forslund et al. [[1]] found that metformin-treated T2DM patients exhibited decreased abundances of Intestinibacter spp. and increased abundances of Escherichia spp. However, the latter was only found in Danish and Swedish populations. In a cross-sectional study that recruited 145 European old women with T2DM, impaired glucose tolerance, or normal glucose tolerance, patients treated with metformin showed different gut microbial composition than those who were not treated with metformin [[12]]. Napolitano et al. also evaluated T2DM with and without metformin monotherapy to characterize the gut-based mechanisms of metformin, and their results showed that Adlercreutzia spp. were significantly elevated in fecal samples of metformin-treated patients [[30]]. Wu et al. [[24]] found that the altered microbiota mainly belonged to the phyla γ-Proteobacteria and Firmicutes. They found an increase in Escherichia spp. and a decrease in Intestinibacter spp., as well as a significant increase in fecal propionate and butyrate concentrations in the metformin group. A possible underlying mechanism for metformin-microbiota interaction is regulating the expression of genes encoding for metalloproteins in gut bacteria. These results demonstrate the influence of metformin on gut microbial diversity and the role of the intestine in the glucose-lowering effect of metformin.

Unfortunately, alteration of gut microbiota by metformin may contribute to its GI intolerance [[21]]. Greenway et al. [[27]] reported a case in which a 30-year-old man newly diagnosed with T2DM was treated with a cobiotic supplement containing inulin, beta-glucan, and blueberry pomace extract for 8 weeks. This patient exhibited balanced glycemic control and alleviated GI side effects of metformin. In addition, Burton et al. [[28]] found that the combination of metformin with GI microbiome modulator (GIMM) in T2DM patients who experienced GI intolerance to metformin resulted in better glucose tolerance compared to placebo and significantly improved fasting glucose levels. These results demonstrate that a safe dietary supplement may improve the efficacy and tolerability of metformin, possibly through the alteration of gut microbiota. Thus, gut microbiota may serve as a novel approach to alleviate metformin adverse effects and consequently improve patient compliance.

3. The Effect of Acarbose on Gut Microbiota in T2DM

Accumulating evidence suggests that postprandial blood glucose level is a powerful predictor of diabetic cardiovascular events [[47], [48]]. As a classical α-glucosidase inhibitor, acarbose lowers postprandial blood glucose levels by delaying glucose absorption, as it inhibits the enzyme that cleaves oligosaccharides into mono- and disaccharides in the intestinal lumen [[29]]. The control of postprandial hyperglycemia is especially important in Asia due to the traditional carbohydrate-rich dietary pattern [[49]]. In a randomized, open-label, noninferiority clinical trial recruiting Chinese patients newly diagnosed with T2DM, treatment with acarbose as initial therapy showed similar glucose-lowering efficacy to that of metformin [[50]]. Therefore, acarbose is an effective and safe antidiabetic agent, especially for the control of postprandial hyperglycemia. The major cause of acarbose side effects (e.g., diarrhea, flatulence, and abdominal distention) is the increased delivery of oligosaccharides to the large intestine. However, these side effects can be ameliorated by gradual upward dose titration [[29]]. Previous studies indicated that acarbose treatment could reduce the risk of cardiovascular events in diabetic patients [[51][54]]. The detailed underlying mechanisms for this cardiovascular protective function are only partially understood [[55]], but they can be attributed to the ability of acarbose to neutralize oxidative stress by increasing H2 production in the GI tract (GIT) [[56]]. However, the results of Chang et al. did not support a cardiovascular protective effect of acarbose compared to metformin in Taiwan populations [[57]].

A series of recent clinical trials clarified the relationship between acarbose and gut microbiota. For example, in a clinical study, 95 Chinese T2DM patients were distributed into 2 groups; one group was treated with acarbose while the other was not. At baseline, diabetic patients showed lower levels of Bifidobacterium longum and higher levels of Enterococcus faecalis than healthy volunteers [[55]]. After 4 weeks of treatment, acarbose-treated patients showed increased Bifidobacterium longum and decreased lipopolysaccharide and prothrombin activator inhibitor-1 levels [[55]]. These results suggest that acarbose treatment could alter gut microbiota and reduce the levels of inflammatory cytokines in diabetic patients. Another randomized, double-blind, controlled crossover trial recruiting prediabetic Chinese individuals demonstrated that acarbose treatment significantly altered the diversity and composition of gut microbiota [[58]]. In addition, Gu et al. [[23]] revealed that acarbose could regulate the gut microbiota of T2DM patients, thereby modulating bile acid metabolism and contributing to beneficial effects on host metabolism.

Although α-glucosidase inhibitors have been widely used clinically, there is an ongoing interest in probiotics or gut microbiota as biotherapeutic agents for some metabolic diseases. Panwar et al. [[59]] found that Lactobacillus strains exhibit glucosidase-inhibitory effects and regulate blood glucose responses to carbohydrates in vivo. As mentioned previously, SCFAs play an important role in diabetes mellitus. Acarbose was found to increase serum butyrate levels in individuals with impaired glucose tolerance. The underlying mechanism for this effect might be that acarbose increases the fermentation of insoluble fibers in the colon [[25]]. Similarly, a clinical study showed that butyrate production is significantly increased during acarbose treatment, whereas the production of acetate and propionate is significantly decreased [[26]].

The beneficial effects of acarbose on diabetes mellitus, such as reduction of inflammatory cytokines and regulation of SCFA levels, can be related to the alteration of intestinal microbiota. However, whether there is an association between the cardiovascular protective action of acarbose and gut microbiota is not yet clear.

4. Glucagon-Like Peptide-1 (GLP-1) and Gut Microbiota

Endocrine peptides play an important role in the crosstalk between gut microbiota and host metabolism. Everard and Cani [[60]] reviewed the effects of certain dietary fibers on the gut microbiota and host homeostasis and on the secretion of enteroendocrine peptides. As discussed earlier in this review, gut microbiota ferments nondigestible polysaccharides in the colon producing SCFAs and thus influences host glucose and energy homeostasis. It has been elucidated that SCFAs activate GPR41 and GPR43 and thus regulate the secretion of enteroendocrine peptides [[61][63]]. Known as a gut hormone, GLP-1 is involved in glucose metabolism, appetite regulation, and gastric emptying. The mechanism by which gut microbiota could accelerate the GI motility was mainly attributed to the suppression of GLP-1 receptor expression in the GIT [[64]]. Recently, several studies have proven the significant glucose-lowering effect of GLP-1-based therapies; GLP-1 receptor agonists like exenatide and liraglutide could promote insulin secretion, suppress glucagon levels, slow gastric emptying, accelerate satiety, induce weight loss, and lower the risk of hypoglycemia [[29]]. Grasset et al. [[65]] demonstrated that GLP-1 sensitivity was modulated by gut microbiota through nitric oxide-dependent mechanism in the enteric nervous system. Their results indicated that new hypoglycemic agents based on GLP-1 should focus on the research of patients' intestinal microbiota.

Currently, the association between gut microbiota and intestinal peptides involved in energy and glucose homeostasis has been well reported. However, the relationship between GLP-1 receptor agonists and gut microbiota is not yet clear; further clinical trials are needed to understand this relationship.

5. Other Glucose-Lowering Agents and Gut Microbiota

Pioglitazone is a thiazolidinedione that can reduce insulin resistance by binding to peroxisome proliferator-activated receptor γ (PPAR-γ) nuclear receptor [[29]]. Previous experimental studies identified the difference in gut microbial structure between KKAy mice and C57BL/6J mice by showing a higher abundance of Bacteroides spp. in the intestine of KKAy mice [[66]]. Pioglitazone was shown to improve gut microbial structure of KKAy mice, but it decreased microbial diversity [[66]]. The traditional Chinese medicine Danshensu Bingpian Zhi (DBZ), a PPAR-γ partial agonist, not only improved the phenotypes of metabolic syndrome but also increased the Bacteroidetes/Firmicutes ratio, resulting in an increase in Akkermansia muciniphila and a decrease in Helicobacter marmotae in HFD-fed mice [[67]]. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was also found to improve gut microbial structure. The underlying mechanism is not clear; however, it can be mediated by relieving intestinal wall edema, alleviating intestinal inflammation, and maintaining the intestinal mucosal barrier integrity [[13]]. Vildagliptin, another DPP-4 inhibitor, was found to significantly reduce microbiota diversity in diabetic rats and to normalize the Bacteroidetes/Firmicutes ratio [[68]]. Sodium/glucose cotransporter (SGLT) is a novel therapeutic target in T2DM. LX4211, a dual inhibitor of SGLT1 and SGLT2, could reduce glucose absorption by inhibiting SGLT1 and stimulate the release of GLP-1 and peptide YY. These effects may be mediated by SCFAs produced by cecal fermentation of unabsorbed glucose [[69]]. Although no definite evidence indicates that SGLT inhibitor has direct effects on gut microbiota to improve glycemic control, it should be noted that SGLT inhibition exerts positive effects on metabolic diseases [[70]].

Other glucose-lowering agents such as cathelicidin antimicrobial peptide [[71]], phlorizin [[72]], and transglucosidase [[73]] were also proven to have beneficial modulatory effects on gut microbiota composition, glucose homeostasis, insulin resistance, and β cell function.

Taken together, these studies are of great significance for understanding the role of gut microbiota as novel therapeutic targets in diabetes mellitus. However, further studies are still needed to confirm the hypothesis.

6. Conclusion

In conclusion, the alteration of gut microbiota is a pivotal process in the pathogenesis and progression of metabolic diseases. The association between glucose-lowering agents and gut microbiota is not yet fully understood. Understanding the effects of glucose-lowering agents on gut microbiota is of great importance to further understand the etiopathogenesis, diagnosis, treatment, adverse effects, and prognosis of metabolic diseases.

Acknowledgements

Acknowledgments

The research was supported by the Fund for Science and Technology Development Plan of Jilin Province (20170623092TC-04) to You Lv.

References

  1. K. ForslundF. HildebrandT. NielsenDisentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota2015528758126226610.1038/nature157662-s2.0-8494977241626633628
  2. R. SenderS. FuchsR. MiloRevised estimates for the number of human and bacteria cells in the body2016148, article e100253310.1371/journal.pbio.10025332-s2.0-8498886426227541692
  3. K.-A. LêY. LiX. XuAlterations in fecal Lactobacillus and Bifidobacterium species in type 2 diabetic patients in Southern China population20133p. 49610.3389/fphys.2012.004962-s2.0-8487457998123386831
  4. A. J. CoxN. P. WestA. W. CrippsObesity, inflammation, and the gut microbiota20153320721510.1016/S2213-8587(14)70134-22-s2.0-8492406628925066177
  5. A. V. HartstraK. E. C. BouterF. BäckhedM. NieuwdorpInsights into the role of the microbiome in obesity and type 2 diabetes201538115916510.2337/dc14-07692-s2.0-8492002556125538312
  6. G. BlandinoR. InturriF. LazzaraM. Di RosaL. MalaguarneraImpact of gut microbiota on diabetes mellitus201642530331510.1016/j.diabet.2016.04.0042-s2.0-8496994083427179626
  7. C. L. BoulangeA. L. NevesJ. ChillouxJ. K. NicholsonM. E. DumasImpact of the gut microbiota on inflammation, obesity, and metabolic disease201681p. 4210.1186/s13073-016-0303-22-s2.0-8496393082127098727
  8. R. J. PerryL. PengN. A. BarryAcetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome2016534760621321710.1038/nature183092-s2.0-8497366768427279214
  9. H. PlovierA. EverardC. DruartA purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice201723110711310.1038/nm.42362-s2.0-8499770189927892954
  10. J. SatoA. KanazawaF. IkedaGut dysbiosis and detection of “live gut bacteria” in blood of Japanese patients with type 2 diabetes20143782343235010.2337/dc13-28172-s2.0-8490496607024824547
  11. J. QinY. LiZ. CaiA metagenome-wide association study of gut microbiota in type 2 diabetes20124907418556010.1038/nature114502-s2.0-8486707483123023125
  12. F. H. KarlssonV. TremaroliI. NookaewGut metagenome in European women with normal, impaired and diabetic glucose control201349874529910310.1038/nature121982-s2.0-8487870971623719380
  13. X. YanB. FengP. LiZ. TangL. WangMicroflora disturbance during progression of glucose intolerance and effect of sitagliptin: an animal study2016201610209317110.1155/2016/20931712-s2.0-8498467374127631013
  14. A. P. LiouM. PaziukJ. M. LuevanoS. MachineniP. J. Turnbaugh Jr.L. M. KaplanConserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity20135178, article 178ra14110.1126/scitranslmed.30056872-s2.0-8487613939423536013
  15. P. D. CaniA. M. NeyrinckF. FavaSelective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia200750112374238310.1007/s00125-007-0791-02-s2.0-3484891262717823788
  16. P. TianB. LiC. HeAntidiabetic (type 2) effects of Lactobacillus G15 and Q14 in rats through regulation of intestinal permeability and microbiota2016793789379710.1039/C6FO00831C2-s2.0-8498791235427713957
  17. K. L. WickensC. A. BarthowR. MurphyEarly pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial2017117680481310.1017/S00071145170002892-s2.0-8501710869228367765
  18. A. SalonenL. LahtiJ. SalojarviImpact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men20148112218223010.1038/ismej.2014.632-s2.0-8490823351824763370
  19. G. den BestenK. van EunenA. K. GroenK. VenemaD. J. ReijngoudB. M. BakkerThe role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism20135492325234010.1194/jlr.R0360122-s2.0-8488313907623821742
  20. J. TanC. McKenzieM. PotamitisA. N. ThorburnC. R. MackayL. MaciaChapter Three - the role of short-chain fatty acids in health and disease20141219111910.1016/B978-0-12-800100-4.00003-92-s2.0-8489136346424388214
  21. L. J. McCreightC. J. BaileyE. R. PearsonMetformin and the gastrointestinal tract201659342643510.1007/s00125-015-3844-92-s2.0-8495744049026780750
  22. S. KhanG. JenaSodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: a comparative study with metformin201625412413410.1016/j.cbi.2016.06.0072-s2.0-8497465254327270450
  23. Y. GuX. WangJ. LiAnalyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment201781p. 178510.1038/s41467-017-01682-22-s2.0-8503534177029176714
  24. H. WuE. EsteveV. TremaroliMetformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug201723785085810.1038/nm.43452-s2.0-8502132059028530702
  25. T. M. WoleverJ. L. ChiassonAcarbose raises serum butyrate in human subjects with impaired glucose tolerance2000841576110961161
  26. G. A. WeaverC. T. TangelJ. A. KrauseAcarbose enhances human colonic butyrate production1997127571772310.1093/jn/127.5.7179164992
  27. F. GreenwayS. WangM. HeimanA novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report201451293210.3920/BM2012.00632-s2.0-8489432799523685372
  28. J. H. BurtonM. JohnsonJ. JohnsonD. S. HsiaF. L. GreenwayM. L. HeimanAddition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels20159480881410.1177/19322968155774252-s2.0-8501647856525802471
  29. D. L. Longo201218thNew YorkMcGraw-Hill
  30. A. NapolitanoS. MillerA. W. NichollsNovel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus201497, article e10077810.1371/journal.pone.01007782-s2.0-8490375981124988476
  31. M. D. FullertonS. GalicK. MarcinkoSingle phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin201319121649165410.1038/nm.33722-s2.0-8488988712324185692
  32. F. A. DucaC. D. CôtéB. A. RasmussenMetformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats201521550651110.1038/nm.37872-s2.0-8492917705725849133
  33. R. A. MillerQ. ChuJ. XieM. ForetzB. ViolletM. J. BirnbaumBiguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP2013494743625626010.1038/nature118082-s2.0-8487370752223292513
  34. K. Y. HurM. S. LeeNew mechanisms of metformin action: focusing on mitochondria and the gut20156660060910.1111/jdi.123282-s2.0-8494545524326543531
  35. S. E. InzucchiR. M. BergenstalJ. B. BuseManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)20123561364137910.2337/dc12-04132-s2.0-8486560644022517736
  36. H. FlorezJ. LuoS. Castillo-FlorezImpact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes2010122211212010.3810/pgm.2010.03.21282-s2.0-7795034625420203462
  37. T. DujicK. ZhouL. A. DonnellyR. TavendaleC. N. A. PalmerE. R. PearsonAssociation of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study20156451786179310.2337/db14-13882-s2.0-8496469353925510240
  38. J. B. BuseR. A. DeFronzoJ. RosenstockThe primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies201639219820510.2337/dc15-04882-s2.0-8496209435626285584
  39. C. J. BaileyC. WilcockJ. H. B. ScarpelloMetformin and the intestine20085181552155310.1007/s00125-008-1053-52-s2.0-4814908691618528677
  40. E. BonoraM. CigoliniO. BoselloLack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects198491475110.1185/030079984091095582-s2.0-00213627466373159
  41. F. CabreiroC. AuK. Y. LeungMetformin retards aging in C. elegans by altering microbial folate and methionine metabolism2013153122823910.1016/j.cell.2013.02.0352-s2.0-8487573835123540700
  42. E. Le ChatelierT. NielsenJ. QinRichness of human gut microbiome correlates with metabolic markers2013500746454154610.1038/nature125062-s2.0-84883110880
  43. H. LeeG. KoEffect of metformin on metabolic improvement and gut microbiota201480195935594310.1128/AEM.01357-142-s2.0-8490702115425038099
  44. N. R. ShinJ. C. LeeH. Y. LeeAn increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice201463572773510.1136/gutjnl-2012-3038392-s2.0-8489796012023804561
  45. J. de la Cuesta-ZuluagaN. T. MuellerV. Corrales-AgudeloMetformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid–producing microbiota in the gut2017401546210.2337/dc16-13242-s2.0-8500819226027999002
  46. X. ZhangY. ZhaoJ. XuModulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats201551, article 1440510.1038/srep144052-s2.0-8494213335226396057
  47. The DECODE study groupGlucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria1999354917961762110.1016/s0140-6736(98)12131-12-s2.0-003359210110466661
  48. T. Nakagamithe DECODA Study GroupHyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin200447338539410.1007/s00125-004-1334-62-s2.0-184283357614985967
  49. S. R. JoshiE. StandlN. TongP. ShahS. KalraR. RathodTherapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review201516131959198110.1517/14656566.2015.10708272-s2.0-8493980738026255950
  50. W. YangJ. LiuZ. ShanAcarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial201421465510.1016/S2213-8587(13)70021-42-s2.0-8489017190824622668
  51. J. L. ChiassonR. G. JosseR. GomisAcarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial2003290448649410.1001/jama.290.4.4862-s2.0-003845570312876091
  52. M. HanefeldM. CagatayT. PetrowitschD. NeuserD. PetzinnaM. RuppAcarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies2004251101610.1016/S0195-668X(03)00468-82-s2.0-034672757814683737
  53. J. M. ChenC. W. ChangY. C. LinJ. T. HorngW. H. H. SheuAcarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study20142014681262810.1155/2014/8126282-s2.0-8490487635225197673
  54. E. StandlM. J. TheodorakisM. ErbachO. SchnellJ. TuomilehtoOn the potential of acarbose to reduce cardiovascular disease2014131p. 8110.1186/1475-2840-13-812-s2.0-8489948336224742256
  55. B. SuH. LiuJ. LiAcarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus20157572973910.1111/1753-0407.122322-s2.0-8493855573025327485
  56. Y. SuzukiM. SanoK. HayashidaI. OhsawaS. OhtaK. FukudaAre the effects of α-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract?2009583132157215910.1016/j.febslet.2009.05.0522-s2.0-6764932123819505462
  57. C. H. ChangY. C. ChangJ. W. LinS. T. ChenL. M. ChuangM. S. LaiCardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study201510031121112910.1210/jc.2014-24432-s2.0-8492493401125555040
  58. X. ZhangZ. FangC. ZhangEffects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial20178229330710.1007/s13300-017-0226-y2-s2.0-8501697894528130771
  59. H. PanwarD. CalderwoodI. R. GrantS. GroverB. D. GreenLactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential20145371465147410.1007/s00394-013-0649-92-s2.0-8491879972424414142
  60. A. EverardP. D. CaniGut microbiota and GLP-1201415318919610.1007/s11154-014-9288-62-s2.0-8490625831424789701
  61. B. S. SamuelA. ShaitoT. MotoikeEffects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41200810543167671677210.1073/pnas.08085671052-s2.0-5594909125918931303
  62. M. K. NøhrM. H. PedersenA. GilleGPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes2013154103552356410.1210/en.2013-11422-s2.0-8488469312923885020
  63. G. TolhurstH. HeffronY. S. LamShort-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2201261236437110.2337/db11-10192-s2.0-8485650972422190648
  64. M. YangH. FukuiH. EdaInvolvement of gut microbiota in association between GLP-1/GLP-1 receptor expression and gastrointestinal motility20173124G367G37310.1152/ajpgi.00232.20162-s2.0-8501728813128154011
  65. E. GrassetA. PuelJ. CharpentierA specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism2017261p. 27810.1016/j.cmet.2017.06.0032-s2.0-8502135691628683293
  66. Y. LiL. HanM. XuJ. GuoM. FengX. WangThe primary research on the gut microbes in KKAy mice2014541121910.1007/s12088-013-0410-32-s2.0-8489166339524426161
  67. P. XuF. HongJ. WangDBZ is a putative PPARγ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis2017186111, Part A2690270110.1016/j.bbagen.2017.07.0132-s2.0-8502637653928736228
  68. Q. ZhangX. XiaoM. LiVildagliptin increases butyrate-producing bacteria in the gut of diabetic rats20171210, article e018473510.1371/journal.pone.01847352-s2.0-8503132758629036231
  69. D. R. PowellM. SmithJ. GreerLX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)–mediated absorption of intestinal glucose2013345225025910.1124/jpet.113.2033642-s2.0-8487651916823487174
  70. A. LehmannP. J. HornbyIntestinal SGLT1 in metabolic health and disease201631011G887G89810.1152/ajpgi.00068.20162-s2.0-8498462921527012770
  71. L. D. PoundC. PatrickC. E. EberhardCathelicidin antimicrobial peptide: a novel regulator of islet function, islet regeneration, and selected gut bacteria201564124135414710.2337/db15-07882-s2.0-8496219097726370175
  72. X. MeiX. ZhangZ. WangInsulin sensitivity-enhancing activity of phlorizin is associated with lipopolysaccharide decrease and gut microbiota changes in obese and type 2 diabetes (db/db) mice201664407502751110.1021/acs.jafc.6b034742-s2.0-8499274079327635781
  73. M. SasakiN. OgasawaraY. FunakiTransglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: a randomized double-blind, placebo-controlled study2013131p. 8110.1186/1471-230X-13-812-s2.0-8487787839023657005
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5964532/fullTextXML. The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as type 2 diabetes mellitus.